Somite.ai News
8 articles
growth-positive
חברת Somite.ai בהובלת מדענים ישראלים מנסה לפתור בעיה שמעסיקה חוקרים כבר עשורים: איך לגרום לתא גזע להפוך בדיוק למה שצריך — ובקנה מידה תעשייתי. אם תצליח, תאים ביולוגיים יוכלו להחליף תרופות — ולשקם תפקודים שאבדו
Somite.ai, led by Israeli scientists, is working on a groundbreaking solution to transform stem cells into specific cell types on an industrial scale. This innovation could potentially replace traditional drugs and restore lost functions in the human body. The company is focusing on the precise differentiation of stem cells, which involves exposing them to specific substances at the right time and concentration. If successful, this technology could revolutionize the field of regenerative medicine by providing a scalable method for producing biological cells that can be used therapeutically.
growth-positive
Somite AI secures $47.5 million Series A to expand AI platform for cell therapy | CTech
Somite AI, a biotechnology company specializing in AI tools for human cell therapy, has raised over $47 million in a Series A funding round led by Khosla Ventures. The funding will advance the development of DeltaStem, an AI-driven platform aimed at improving human cell production for therapeutic use. The company is targeting applications in Type 1 Diabetes, orthopedic injuries, muscular diseases, and blood disorders. Somite AI has also appointed Fidji Simo as its new CEO of Applications and Board Member. The company aims to revolutionize cell therapy by leveraging AI to enhance the efficiency and scalability of cell production.
InvestmentManagement Changes
growth-positive
Somite AI is building DeltaStem, a platform and foundation model designed to revolutionize the production of human cells.
Somite AI, a cell therapy development company, has secured $47 million in a Series A financing round led by Khosla Ventures, with contributions from several other notable investors. The company is developing DeltaStem, a platform aimed at revolutionizing human cell production by leveraging foundation models and proprietary AI. This funding will accelerate the development of therapeutic programs for various diseases and enhance the DeltaStem platforms capabilities. Somite AI, co-founded by Dr. Micha Breakstone and Dr. Jonathan Rosenfeld, is focused on creating a foundation model for human cells, aiming for significant advancements in developmental biology.
Investment
growth-positive
Before joining Somite.ai, Kivity served as Chief of Staff and first U.S. employee at 4M Analytics. He joins the company after completing over 250 days of reserve duty in the Iron Swords war as a Deputy Battalion Commander in Gaza.
Somite.ai, an Israeli TechBio company specializing in AI-driven cell replacement therapies, has appointed Shai Kivity as its VP of Strategy & Operations. Kivity brings extensive experience in business development and strategy, having previously served as Chief of Staff at 4M Analytics and in various roles at Alvarez & Marsal. His appointment is expected to accelerate the companys growth and strategic development. Additionally, Somite.ai recently completed a pre-seed funding round of over $10 million, with investments from Astellas Venture Management and Montage Ventures. These developments mark significant steps towards advancing Somite.ais mission in AI-driven drug development.
Management ChangesInvestment
growth-positive
Somite.ai takes pre-seed to $10M as it eyes to become ‘the OpenAI of stem cell biology’ | CTech
Somite.ai, a TechBio company specializing in AI-driven cell replacement therapies, has secured a $4.8 million extension to its initial pre-seed round, bringing its total funding to $10 million. This extension comes just six months after the initial raise. The new funding round includes investments from Astellas Venture Management and Montage Ventures, who will join as Board Observers. The funds will be used to advance the companys AI platform, AlphaStem, and to progress clinical programs SMT-M01 and SMT-B01. The company aims to leverage AI to produce human tissue for cell therapies targeting diseases such as diabetes, obesity, and muscular dystrophies.
Investment
growth-positive
Somite raises $5.3 million to incorporate AI in stem cell therapy | CTech
Somite, a company aiming to become a leader in stem cell biology, has raised $5.3 million in pre-seed funding. The investment round was led by Israeli VC TechAviv and included participation from Austin-based VCs Next Coast Ventures, Trust Ventures, Texas Venture Partners, and NY-based Lerer Hippeau. Somite is developing the AlphaStem platform to unlock the principles of cell differentiation and introduce new therapies. The founding team includes CEO Micha Breakstone, who previously sold Chorus.ai for $575 million, and several prominent scientists. The company aims to leverage AI to produce human tissue for cell therapies, potentially curing diseases like Diabetes, Obesity, and Muscular Dystrophies.
InvestmentPartners
growth-positive
Forbes: This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market
Somite.ai, a startup founded by five scientists, aims to leverage AI to produce human tissue for cell therapies. The company focuses on using embryo digital twins and AI to guide the discovery and optimization of cell replacement therapy (CRT). Somite.ai recently raised $5.3 million in pre-seed funding led by TechAviv, with participation from Next Coast Ventures, Trust Ventures, Texas Venture Partners, and Lerer Hippeau. The startup has already hired two translational scientists and plans to bring its first therapeutic asset to phase-1 clinical trials within the next two years. The market for the therapies they aim to address is estimated at $250 billion.
InvestmentExpand
growth-positive
Together with Harvard and MIT scientists, Micha Breakstone founded Somite.ai, which combines stem cell and AI techniques to develop new therapies.
Somite.ai, founded by Micha Breakstone and a team of prominent scientists, aims to revolutionize stem cell therapy. The company focuses on manipulating the surroundings of cells to influence their differentiation, with the first goal being muscle stem cells for treating Duchenne Muscular Dystrophy. Clinical trials are expected to begin in two years. The company has raised several million dollars from investors including Lerer Hippeau, Mark VC, and DarkMode. Breakstones previous company, NeuraLight, had $20 million in the bank when he left due to strategic disagreements.
Investment
